265 related articles for article (PubMed ID: 31388979)
1. Proteome-wide subtractive approach to prioritize a hypothetical protein of XDR-Mycobacterium tuberculosis as potential drug target.
Uddin R; Siddiqui QN; Sufian M; Azam SS; Wadood A
Genes Genomics; 2019 Nov; 41(11):1281-1292. PubMed ID: 31388979
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
[TBL] [Abstract][Full Text] [Related]
3. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
4. Next-Generation Sequencing for Characterizing Drug Resistance-Conferring Mycobacterium tuberculosis Genes from Clinical Isolates in the Ukraine.
Daum LT; Konstantynovska OS; Solodiankin OS; Liashenko OO; Poteiko PI; Bolotin VI; Hrek II; Rohozhyn AV; Rodriguez JD; Fischer GW; Chambers JP; Gerilovych AP
J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29563202
[TBL] [Abstract][Full Text] [Related]
5. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
[TBL] [Abstract][Full Text] [Related]
6. Integrated bioinformatics based subtractive genomics approach to decipher the therapeutic function of hypothetical proteins from Salmonella typhi XDR H-58 strain.
Khan K; Uddin R
Biotechnol Lett; 2022 Feb; 44(2):279-298. PubMed ID: 35037232
[TBL] [Abstract][Full Text] [Related]
7. Comparison of
Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
[TBL] [Abstract][Full Text] [Related]
8. 4H-1,3-Benzothiazin-4-one a Promising Class Against MDR/XDR-TB.
de Souza MVN; Nogueira TCM
Curr Top Med Chem; 2019; 19(8):567-578. PubMed ID: 30834835
[TBL] [Abstract][Full Text] [Related]
9. Proteomic characterization of Mycobacterium tuberculosis reveals potential targets of bostrycin.
Yuan P; He L; Chen D; Sun Y; Ge Z; Shen D; Lu Y
J Proteomics; 2020 Feb; 212():103576. PubMed ID: 31706025
[TBL] [Abstract][Full Text] [Related]
10. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
11. Application of a subtractive genomics approach for in silico identification and characterization of novel drug targets in Mycobacterium tuberculosis F11.
Hosen MI; Tanmoy AM; Mahbuba DA; Salma U; Nazim M; Islam MT; Akhteruzzaman S
Interdiscip Sci; 2014 Mar; 6(1):48-56. PubMed ID: 24464704
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterial interspersed repetitive unit typing and mutational profile for multidrug-resistant and extensively drug-resistant tuberculosis surveillance in Portugal: a 3-year period overview.
Silva C; Perdigão J; Jordão L; Portugal I
Int J Antimicrob Agents; 2014 Dec; 44(6):546-51. PubMed ID: 25270633
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China: 2006 versus 2012.
Yin QQ; Jiao WW; Li QJ; Xu F; Li JQ; Sun L; Li YJ; Huang HR; Shen AD
BMC Microbiol; 2016 May; 16():85. PubMed ID: 27176471
[TBL] [Abstract][Full Text] [Related]
14. Extensively drug-resistant tuberculosis: current challenges and threats.
Jain A; Mondal R
FEMS Immunol Med Microbiol; 2008 Jul; 53(2):145-50. PubMed ID: 18479439
[TBL] [Abstract][Full Text] [Related]
15. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
Bueno RV; Braga RC; Segretti ND; Ferreira EI; Trossini GH; Andrade CH
Curr Pharm Des; 2014; 20(27):4474-85. PubMed ID: 24245758
[TBL] [Abstract][Full Text] [Related]
16. RNA expression analysis of efflux pump genes in clinical isolates of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in South Korea.
Oh TS; Kim YJ; Kang HY; Kim CK; Cho SY; Lee HJ
Infect Genet Evol; 2017 Apr; 49():111-115. PubMed ID: 28062386
[TBL] [Abstract][Full Text] [Related]
17. An
Kumar S; Sahu P; Jena L
Int J Mycobacteriol; 2019; 8(3):252-261. PubMed ID: 31512601
[TBL] [Abstract][Full Text] [Related]
18. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
Wen S; Jing W; Zhang T; Zong Z; Xue Y; Shang Y; Wang F; Huang H; Chu N; Pang Y
Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1293-1296. PubMed ID: 30953211
[TBL] [Abstract][Full Text] [Related]
19. Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-
Hameed HMA; Islam MM; Chhotaray C; Wang C; Liu Y; Tan Y; Li X; Tan S; Delorme V; Yew WW; Liu J; Zhang T
Front Cell Infect Microbiol; 2018; 8():114. PubMed ID: 29755957
[TBL] [Abstract][Full Text] [Related]
20. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
